Headache Associated with Myasthenia Gravis: The Impact of Mild Ocular Symptoms by Nishimoto, Yoshinori et al.
SAGE-Hindawi Access to Research
Autoimmune Diseases
Volume 2011, Article ID 840364, 4 pages
doi:10.4061/2011/840364
Clinical Study
HeadacheAssociated withMyastheniaGravis:
TheImpactofMildOcularSymptoms
Yoshinori Nishimoto,1 Shigeaki Suzuki,1 Kimiaki Utsugisawa,2 Yuriko Nagane,2
Mamoru Shibata,1 Toshihiko Shimizu,1 and NorihiroSuzuki1
1Department of Neurology, School of Medicine, Keio University, 35 Shinanomachi, Shinjuku-ku, Tokyo 160-8582, Japan
2Department of Neurology, Hanamaki General Hospital, 4-28 Kajoh-chou, Hanamaki 025-0075, Japan
Correspondence should be addressed to Yoshinori Nishimoto, ynishimo@z3.keio.jp
Received 5 April 2011; Revised 6 June 2011; Accepted 6 June 2011
Academic Editor: Johan A. Aarli
Copyright © 2011 Yoshinori Nishimoto et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
Myastheniagravis(MG)patientsvisitingoutpatientclinicsfrequentlycomplainofheadache.However,therehavebeenfewreports
on the relation between chronic headache and myasthenia gravis (MG). We aimed to investigate whether MG symptoms aﬀect the
development or worsening of chronic headache. Among the 184 MG patients who were followed at the MG clinics, tension-
type headache was observed in 71 (38.6%) patients and 9 (4.9%) complained of migraine. Twenty-ﬁve (13.6%) complained that
headache appeared or was exacerbated after the MG onset. The investigation into diﬀerences in the clinical characteristics of the
MGpatientsshowedthatwomentendedtosuﬀerfromMG-associatedheadachemoreoftenthanmen.Logisticregressionanalyses
revealedthatfemalegenderandmildocularsymptomswereindependentlypredictiveofheadacheassociatedwithMG.Ourresults
suggest that treatment of chronic headache should be required to improve the quality of life in MG patients.
1.Introduction
Headache is one of the most common neurological symp-
toms. At our clinics, we have found that some myasthenia
gravis (MG) patients complain of headache more than the
known MG-related symptoms. In these cases, the headaches
could have a more negative impact on the quality of
daily life than the other MG manifestations. It seemed
that certain MG symptoms induce the development or
worsening of headache, but there have been only a few case
reports concerning headache in MG patients [1, 2]. On
the other hand, some major neurological diseases, including
Parkinson’s disease [3, 4] and multiple sclerosis [5, 6], have
been reported to be associated with headache. In this paper,
to investigate the relationship between headache and MG,
we examined whether each of the MG symptoms could be
a cause of headache in MG patients.
2. Methods
2.1. Patient Selection and Diagnosis of Headaches. We studied
184patients with MG (60men and 124women; mean ± SD
age, 55.9 ± 17.0), who were followed at the MG clinics
of 2institutions, Keio University Hospital and Hanamaki
General Hospital in Japan, from November 2007 to April
2008 and had been followed up for at least 1year. The
diagnosis of MG was made based on the following criteria:
typical history and signs of ﬂuctuating weakness of volun-
tary muscles, presence of serum antiacetylcholine receptor
antibodies (AChR Ab), deﬁnite clinical improvement on
injection of the cholinesterase inhibitor, edrophonium, and
decremental pattern on repetitive nerve stimulation [7].
The mean ± SD onset age and duration after onset in
the 184patients were 45.9 ± 18.0years old and 8.4 ±
8.1years, respectively. First, among MG patients, we diag-
nosed primary headaches according to the International
Classiﬁcation of Headache Disorders: 2nd edition (ICHD-
II), based on physical and neurological examinations and
head CT and/or MRI. Secondly, we examined the MG
symptoms and characteristics of their headaches in detail in
addition to using the questionnaire as a reference.
2.2. Division of the QMG Score. To evaluate which symp-
toms of MG appeared when their headache occurred, MG2 Autoimmune Diseases
symptoms at the outpatient clinic were graded according to
a quantitative MG scoring system (QMG score) consisting of
13items [8].AsBhanushalietal.separatedthreeoftheQMG
score items as a discrete ocular component (ocular-QMG
score) in order to monitor the severity of ocular symptoms
independently, we divided the test items of the QMG score
into four subgroups according to their proximity in the
body [9]. That is, we deﬁned double vision on lateral gaze,
ptosis, and facial muscle weakness as “ocular symptoms,”
swallowing and dysarthria after counting aloud from 1 to
50 as “bulbar symptoms,” outstretching of either an arm
or leg, or gripping of either hand as “limb symptoms,”
and vital capacity % predicted and head lifting as “trunk
symptoms.” All data and clinical information were obtained
after the patients had given their informed consent, and the
study was approved by the institutional review board of each
hospital.
2.3. Statistical Analyses. Statistical assessments in this study,
including Student’s t-test, chi-square test, and logistic regres-
sion analyses, were performed using a statistical software
program (StatView 5.0; SAS Institute Inc., Cary, NC).
Values of P< 0.05 were considered to indicate statistical
signiﬁcance.
3. Results
3.1. Analysis of Headache in MG Patients. First, with respect
to primary headache, 71 of the 184MG patients (38.6%)
were diagnosed with tension-type headache, and 4.9%
(9/184) were diagnosed with migraine based on the ICHD-II
[10]. Next, in our examination of the relationship between
the onset of MG and headache, 13.6% (25/184) of the MG
patients experienced headache associated with MG which
appeared or was exacerbated after they were diagnosed
with MG. Headache worsened in 15patients, and headache
initially appeared in 10patients after MG onset.
The characteristics of MG-associated headache are
shown in Figure 1. In regard to frequency, 48% (12/25)
of the patients with MG-associated headache complained
of headache 1–3times a month. 20% (5/25) had headache
every day. 16% had headache only irregularly over a certain
period. 12% of patients had headache 1–4times per week,
with one patient complaining of severe pain more than
twice a day (Figure 1(a)). The results in regard to the sites
of headache associated with MG showed that deep in the
orbit and back of the neck were the most favorite sites
seen in 84% (21/25) and 60% (15/25) of the patients with
MG-associated headache, respectively. Headache also often
occurredinthetemporalportion(32%),onesideofthehead
(32%), the frontal portion (28%) or the whole head (20%).
Thesurroundingsoftheorbit(12%),theface(12%),andthe
parietal portion (8%) were rarely documented as the sites of
headache associated with MG (Figure 1(b)).
We also evaluated which symptoms of MG developed
during the period of headache. Head dropping (68%) and
ptosis (60%) were most frequently observed. General fatigue
(56%) and double vision (52%) also often occurred, and
limb weakness, chewing diﬃculty, shortness of breath, and
talking diﬃculty were complications in 24%, 16%, 12%, and
8% of patients, respectively.
Then, we investigated the demographic and clinical
features of MG patients who experienced appearance or
exacerbation of headache after MG onset and those who did
not (Table 1). MG symptoms at the outpatient clinic were
evaluated according to the quantitative MG scoring system
(QMG score) [8]. As Bhanushali et al. described previously
[9], we divided the test items of the QMG score into
4subgroups, where double vision on lateral gaze, ptosis, and
facial muscle weakness belonged to the subgroup of “ocular
symptoms.” The results suggested that there were markedly
signiﬁcant diﬀerences in female gender (P = 0.03) between
the two groups, whereas there were no diﬀerences in mean
age, follow-up period, seropositivity of autoantibodies to
the acetylcholine receptor, presence of thymoma, or history
of treatments, including thymectomy and administration of
prednisolone and calcineurin inhibitor (Table 1). Notably,
there were also no signiﬁcant diﬀerences in occurrence or
aggravation of headache according to the severity of QMG
score.
3.2. Clinical Factors Associated with Aggravation of Headache
in MG Patients. Finally, we examined which types of clinical
factors aﬀected headache in the MG patients by univariate
logistic regression analysis. To consider the possibility of an
association between the severity of MG and headache, each
of the four types of symptoms, that is, ocular, bulbar, limb,
and trunk, was separated into mild and moderate subgroups
based on the mean score. The clinical factors for which
the probability values were less than 0.05 in the univariate
regression analysis, which were age (1.0 and 0.04 for the
odds ratio and P value, resp.), female gender (4.3 and 0.02),
age at onset (0.98 and 0.04), mild ocular symptoms (4.8
and 0.002), mild bulbar symptoms (3.1 and 0.04), and total
QMG score (1.1 and 0.04), were further entered into the
multivariate logistic regression analysis for determination of
theindependentclinicalfactorsaﬀectingheadacheassociated
with MG (Table 2). Multivariate logistic regression analysis
revealed that female gender (4.5 and 0.02 for the odds ratio
and P-value, resp.) and mild ocular symptoms with QMG
1–3 in the ocular score (7.2 and 0.0005) were independent
clinical factors linked with headache associated with MG.
4. Discussion
This study disclosed that 38.6% of the MG patients had
tension-type headache and 4.9% had migraine according to
the ICHD-II [10]. Additionally, it was notable that 13.6%
of the MG patients experienced headache associated with
MG. In regard to the general characteristics of MG patients,
headache was aﬀected by female gender but not by the age,
the disease duration, or the severity of symptoms. Moreover,
the logistic regression analysis suggested that both female
gender and mild ocular symptoms might have inﬂuence on
headache associated with MG.
Mildocularsymptomsindicateaslightdegreeofdiplopia
or ptosis in MG patients, which ﬂuctuates dynamically and
might lead to worsening of headache. In contrast, the MGAutoimmune Diseases 3
Table 1: Demographic and clinical features of patients with MG-associated headache.
MG-associated headache (+)(n = 25) MG-associated headache (−)(n = 159) P value
Female gender 22 (88%) 102 (64%) ∗0.03
Mean age, y (range) 49.4 ± 17.2 57.0 ± 16.8 n.s.
Mean disease duration, y (range) 9.2 ± 7.6 8.2 ± 8.2 n.s.
AChR-Ab positive 16 (64%) 118 (74%) n.s.
Thymoma present 2 (8%) 37 (23%) n.s.
Thymectomy 9 (36%) 74 (47%) n.s.
PSL administration 15 (60%) 84 (53%) n.s.
CNI administration 8 (32%) 43 (27%) n.s.
QMG scores
Total 8.4 ± 4.9 6.2 ± 4.6 n.s.
Ocular symptoms 2.2 ± 1.6 1.6 ± 1.8 n.s.
Bulbar symptoms 0.3 ± 0.5 0.2 ± 0.6 n.s.
Limb symptoms 4.9 ± 3.0 3.7 ± 2.8 n.s.
Trunk symptoms 1.1 ± 0.7 0.8 ± 0.8 n.s.
∗P-value < 0.05.
MG: myasthenia gravis; QMG: quantitative myasthenia gravis scoring; n.s.: not signiﬁcant; AChR-Ab, autoantibodies to the acetylcholine receptor;P S L :
prednisolone; CNI: calcineurin inhibitor.
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Figure 1: The characteristics of MG-associated headache. (a) The frequency of headache associated with MG (N = 25). (b) The rates of the
patients, who complained of MG-associated headache in each site. Note that headache associated with MG occurs deeply in the orbit most
frequently.
patients with severe QMG scores (scores greater than 3)
would have ﬁxed symptoms with little change, which would
less frequently lead to headache associated with MG. These
facts suggest that ﬂuctuation of the MG ocular symptoms
could actually underlie the headache of patients with MG.
When we must classify MG-associated headache based on
the ICHD-II [10], it should be most similar to secondary
headache as shown in the code 11.3.3 “Headache attributed
to heterophoria or heterotropia.” However, MG per se is
not included as one of the causative factors of secondary
headaches in the ICHD-II.
MG is an autoimmune disease of the neuromuscular
junction and does not aﬀect the central pain pathway or
other sensory tracts. We speculate that there is no direct
pathologic relation between MG and headache. Indeed,
since anticholinesterase agents had a partial or no eﬀect
on headache associated with MG, NSAIDs were eventually
required to alleviate the pain in many cases. Based on these
results, together with the results of analyses on the charac-
teristics of MG-associated headache (Figure 1), it is diﬃcult
to distinguish MG-associated headache from tension-type
headache. It was noteworthy that most of MG-associated4 Autoimmune Diseases
Table 2: Inﬂuences of clinical factors on headache associated with
MG.
Variable Odds ratio (95% CI) P-value
Age (years) 1.0 (0.9–1.0) n.s.
Female gender 4.5 (1.2–16.8) ∗0.02
Age at onset (years) 1.0 (1.0–1.1) n.s.
Mild ocular symptoms (QMG 1-3) 7.2 (2.4–21.8) ∗0.0005
Mild bulbar symptoms (QMG 1-3) 2.3 (0.4–14.6) n.s.
Total QMG score 1.1 (0.9–1.3) n.s.
∗P-value < 0.05.
MG: myasthenia gravis; n.s.: not signiﬁcant; QMG: quantitative myasthenia
gravis scoring; CI: conﬁdence interval.
headache could be diagnosed with tension-type headache
on the ICHD-II even when the suﬀered portion in 32%
of the patients with MG-associated headache was restricted
unilaterally (Figure 1(b)). Head dropping and ﬂuctuation of
ptosis and diplopia would accelerate visual fatigue and/or
stiﬀness of the neck, which could be the most important
precipitating factors of headache associated with MG.
It should be mentioned that this cross-sectional study
has potential limitations related to recall bias and selection
bias. A recall bias may have been present because patients
with more severe MG symptoms may not have paid as much
attention to their headache, and thus patients with mild
ocular symptoms might have complained of headache more
frequently. It would be another recall bias that the duration
after onset of MG was as long as 8.4years. Questionnaire
asking the change of their headache characteristics between
before and after the onset point had the most important
role in providing the information for this study, but the
duration might have been too long for completely accurate
data. On the other hand, a selection bias may have played
a role because the subjects of this study were limited to
Japanese MG patients, who were receiving regular outpatient
treatments. Due to this potential selection, neither MG
patients with extremely mild symptoms nor critically severe
conditionsmighthavebeenincludedinthisstudy.Wecannot
exclude these biased factors, and further investigations with
a greater number of patients in all grades of MG symptoms
will be needed.
In conclusion, headaches could disturb the quality of life
of MG patients greatly even when their general symptoms
of MG are comparatively well controlled. Careful attention
to appearance or aggravation of headache in MG patients
is important to improve their quality of life, especially in
women with mild ocular symptoms.
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